BPC-157 + TB-500

Accelerating

bpc-157-tb-500 appears in 1,406 indexed publications going back to 1982, including 67 in the past twelve months. 17 registered trials appear on ClinicalTrials.gov.

1,406
Indexed publications
67
Past 12 months, against 32 the year before
17
Registered clinical trials
22,422
Monthly readers on Wikipedia, down 4%

On This Figure
BPC-157 + TB-500 is a blend. These figures combine its components (BPC-157, TB-500), so totals are an upper bound where a single paper covers more than one of them.

Research Activity

Publication history

How much work has been indexed each year, from Europe PMC. Momentum is measured over a trailing twelve months rather than calendar years, so a partial current year never reads as a decline.

20152026

Publications per year. The final bar is the current year, still in progress.

Indexed publications per year
20155
20168
201711
20189
20196
202011
202119
202212
202310
20245
202519
202627
Public Attention

Who is looking it up

Monthly readers of the BPC-157 + TB-500 article on English Wikipedia. An independent measure of curiosity, which often moves quite differently from the evidence.

2025-082026-07
Clinical Trials

The registered pipeline

Early Phase 1
0
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0

Phase distribution across the most recently updated registered trials.

References

Most recent work

The newest indexed records mentioning BPC-157 + TB-500, listed by publication date. Titles are shown as published and link to their source. Inclusion here is a record of what exists, not a judgement of what it shows.

  1. 2026-08-01·Clinical science (London, England : 1979)

    Thymosin β4 alleviates sepsis-associated acute kidney injury by suppressing MAPK signaling pathway

    Ouyang X, Long Z, Xu X et al.

  2. 2026-07-27·The Analyst

    Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices

    Mazzarino M, Colpaert T, Deventer K et al.

  3. 2026-07-10·Experimental eye research

    Understanding the effects of ciprofloxacin on corneal epithelial cells: a study using electric cell-substrate impedance sensing (ECIS) technology

    Banga L, Shawky M, Ebrahim F et al.

  4. 2026-07-01·Current sports medicine reports

    Effects of Supplementation in Masters Athletes and Older Adults: A Narrative Review

    Nguyen C, Allen MR, Hornburg K et al.

  5. 2026-07-01·Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

    [Thymosin β4 inhibits pyroptosis in BV2 microglial cells: a mechanistic study <i>in vitro</i>]

    Li YX, Chen CL, Zheng SD et al.

  6. 2026-06-01·Journal of physiology and pharmacology : an official journal of the Polish Physiological Society

    Stable pentadecapeptide therapy counteracts gentamicin-induced nephrotoxicity via nitric oxide-system modulation: evidence from a triple nitric oxide-agent approach in rats

    Vukoja I, Vlainic J, Francina M et al.

  7. 2026-06-01·Investigative ophthalmology & visual science

    Reparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function

    Ebrahim AS, Liu L, Carion TW et al.

  8. 2026-05-30·Pharmaceuticals (Basel, Switzerland)

    Unilateral Adrenalectomy, and the Stable Pentadecapeptide BPC 157 as Therapy in Rats-A Cytoprotection Approach

    Smoday IM, Vukovic V, Oroz K et al.

In the Catalogue

BPC-157 + TB-500 available from Polaris Research

Supplied as research materials for laboratory use. Free express delivery Australia wide.

Sources

Publication data from Europe PMC. Clinical trial data from ClinicalTrials.gov, U.S. National Library of Medicine. Public attention from Wikimedia pageview data. Evidence grades from reptides.co. We report counts and dates from these sources and link every record to its origin, we do not summarise findings. Last synced 2026-08-02.